Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Viral target and metabolism‐based rationale for combined use of recently authorized small molecule COVID‐19 medicines: Molnupiravir, nirmatrelvir, and remdesivir

18 Mar 2023

Abstract excerpt

Abstract The COVID‐19 pandemic remains a major health concern worldwide, and SARS‐CoV‐2 is continuously evolving. There is an urgent need to identify new antiviral drugs and develop novel therapeutic strategies. Combined use of newly authorized COVID‐19 medicines including molnupiravir, nirmatrelvir, and remdesivir has been actively pursued. Mechanistically, nirmatrelvir inhibits SARS‐CoV‐2 replication by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Drug Discovery Methods
Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36931725
DOI: 10.1111/fcp.12889

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Viral target and metabolism‐based rationale for combined use of recently authorized small molecule COVID‐19 medicines: Molnupiravir, nirmatrelvir, and remdesivirPMID 36931725Read ↗

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 VariantsSemantic proximity Read ↗

Molecular Mechanisms of the Medicines for COVID-19Semantic proximity Read ↗

Recent advances in small-molecular therapeutics for COVID-19Semantic proximity Read ↗

An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challengesSemantic proximity Read ↗

Potential Therapeutic Agents and Associated Bioassay Data for COVID-19 and Related Human Coronavirus InfectionsSemantic proximity Read ↗

RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug DiscoverySemantic proximity Read ↗

Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.Semantic proximity Read ↗

Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel StrategiesSemantic proximity Read ↗

Small Molecule Drugs Targeting Viral PolymerasesSemantic proximity Read ↗

An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations.Semantic proximity Read ↗

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral ActivitySemantic proximity Read ↗

Existing Antiviral Options Against SARS-CoV-2 Replication in COVID-19 PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.